Liu Xiaoshuang, Tang Chao, Wen Guodao, Zhong Chunyu, Yang Jin, Zhu Junhao, Ma Chiyuan
The State Key Laboratory of Pharmaceutical Biotechnology and Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, School of Life Science, NJU Advanced Institute for Life Sciences, Nanjing University, Nanjing, China.
Department of Neurosurgery, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China.
Front Endocrinol (Lausanne). 2019 Jan 22;9:768. doi: 10.3389/fendo.2018.00768. eCollection 2018.
Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. However, the pathways of either dopamine or its agonists that lead to the death of cells are incompletely understood and some are even conflicting conclusions. The main aim of this paper is to review the different pathways of dopamine and its agonists in prolactinomas to help to gain a better understanding of their functions and drug resistance mechanisms.
溴隐亭和卡麦角林等多巴胺激动剂是治疗泌乳素瘤的主要药物,可抑制泌乳素分泌并缩小肿瘤大小。然而,多巴胺及其激动剂导致细胞死亡的途径尚未完全明确,甚至有些结论相互矛盾。本文的主要目的是综述多巴胺及其激动剂在泌乳素瘤中的不同作用途径,以更好地了解其功能及耐药机制。